ABL Biotechnologies Ltd - Stock Valuation and Financial Performance

BSE: 526955 | NSE: | Pharmaceuticals & Drugs | Small Cap

BSE Share Price
Not Listed

DeciZen - make an informed investing decision on ABL Biotechnologies

M-Cap below 100cr DeciZen not available

ABL Biotechnologies stock performance -

mw4me loader
P/E Ratio (SA):
0.00
Market Cap:
0.7 Cr.
52-wk low:
0.8
52-wk high:
0.8

Is an attractive stock to invest in?

1. Is a good quality company?

Data is not available for this company.

2. Is undervalued or overvalued?

No data found

3. Is a good buy now?

No data found

10 Year X-Ray of ABL Biotechnologies:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.

Value Creation

Value Creation Index Colour Code Guide

Mar'03Mar'04Mar'05Mar'06Mar'07Mar'08Mar'09Mar'10Mar'11Mar'12TTM
ROCE % -3.5%2.8%12.1%24.9%15.8%10.5%-0.4%-43.7%-1.7%-0.5%-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 0.22.65.879.316.98.22.2000
Sales YoY Gr.-1,400%127.5%20.9%32.2%81.9%-51.7%-72.8%-98.2%-100%-
Adj EPS -0.40.214.15.34.4-1.2-25.2-0.7-0.2-0.2
YoY Gr.-NA325%302%28.3%-16.9%-126.8%NANANA-
BVPS (₹) 5.65.56.2916.620.443.318.417.817.617.3
Adj Net
Profit
-0.10.10.41.72.21.8-1-20.6-0.6-0.20
Cash Flow from Ops. 00.60.6-3.61.8-1.70.8-9.6-0.5-0.1-
Debt/CF from Ops. 78.51.82.8-1.45.7-8.621.3-1.7-36.2-148.9-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales -100%-100%-100%-100%
Adj EPS NA-153%NANA
BVPS13.6%1.2%-25.9%-0.9%
Share Price - - - -

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'03Mar'04Mar'05Mar'06Mar'07Mar'08Mar'09Mar'10Mar'11Mar'12TTM
Return on
Equity %
-5.23.713.74024.614.3-3.6-69.3-3.2-1-0.9
Op. Profit
Mgn %
-1147.711.417.718.619.24.9-899.2-12660NAN
Net Profit
Mgn %
-83.63.97.22423.310.6-11.7-927.8-14250-INF
Debt to
Equity
0.60.50.61.41.51.70.51.11.21.20.7
Working Cap
Days
31068691822642536461,61374,66200
Cash Conv.
Cycle
-179-79-71-51-39-19-34-21-9,35600

Recent Performance Summary

No data to display

Return on Equity has declined versus last 3 years average to %

Sales growth has been subdued in last 3 years %

Sales growth is not so good in last 4 quarters at %

Latest Financials - ABL Biotechnologies Ltd.

Standalone Consolidated
TTM EPS (₹) -0.2 -0.2
TTM Sales (₹ Cr.) 0 0
BVPS (₹.) 17.3 17.3
Reserves (₹ Cr.) 6 6
P/BV 0.05 0.05
PE 0.00 0.00
From the Market
52 Week Low / High (₹) 0.75 / 0.81
All Time Low / High (₹) 0.73 / 222.00
Market Cap (₹ Cr.) 0.7
Equity (₹ Cr.) 8.2
Face Value (₹) 10
Industry PE 48.5

Management X-Ray of ABL Biotechnologies:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of ABL Biotechnologies

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'03Mar'04Mar'05Mar'06Mar'07Mar'08Mar'09Mar'10Mar'11Mar'12
Sales0.172.555.807.019.2716.868.152.220.040
Operating Expenses 0.362.365.145.767.5613.687.7722.230.570.12
Manufacturing Costs0.060.731.601.641.381.561.960.990.010
Material Costs0.080.881.982.734.569.583.583.400.070
Employee Cost 0.070.220.610.600.731.291.190.780.130.02
Other Costs 0.150.530.940.790.891.261.0417.050.370.10
Operating Profit -0.190.190.661.241.713.180.38-20-0.53-0.12
Operating Profit Margin (%) -114.0%7.6%11.4%17.7%18.5%18.9%4.7%-899.0%-1,266.0%-
Other Income 0.140.0301.011.570.140.01000.01
Interest 00.020.150.280.621.161.120.5200
Depreciation 0.090.110.150.170.210.220.230.120.070.07
Exceptional Items 0.0200.280000000
Profit Before Tax -0.130.100.651.802.461.95-0.95-20.64-0.60-0.18
Tax 000.030.130.310.190.01000
Profit After Tax -0.130.100.611.682.151.75-0.97-20.64-0.60-0.18
PAT Margin (%) -76.3%3.8%10.5%24.0%23.2%10.4%-11.9%-927.0%-1,425.0%-
Adjusted EPS (₹)-0.30.21.54.15.24.3-1.2-25.2-0.7-0.2
Dividend Payout Ratio (%)0%0%0%0%0%0%0%0%0%0%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'03Mar'04Mar'05Mar'06Mar'07Mar'08Mar'09Mar'10Mar'11Mar'12

Equity and Liabilities

Shareholders Fund 2.652.753.365.0410.8612.6240.2119.3318.7418.56
Share Capital 4.104.104.104.104.104.108.208.208.208.20
Reserves -1.45-1.35-0.740.946.768.5232.0111.1310.5410.36
Minority Interest0000000000
Debt1.261.041.515.1710.1314.1516.5916.6616.9717.10
Long Term Debt1.261.041.515.1710.1314.1516.5916.6612.6512.79
Short Term Debt000000004.314.31
Trade Payables0.291.221.962.724.427.298.388.869.539.43
Others Liabilities 0.120.300.981.611.980.550.500.7400
Total Liabilities 4.325.317.8114.5427.4034.6165.6945.6045.2345.10

Fixed Assets

Gross Block3.123.483.683.668.568.968.9835.9835.7135.72
Accumulated Depreciation0.630.740.890.981.181.371.560.880.850.92
Net Fixed Assets2.482.732.792.677.387.597.4335.1034.8634.80
CWIP 00005.927.347.62000
Investments 1.301.302.402.401.301.301.301.301.301.31
Inventories0.050.501.361.632.482.9730.0700
Trade Receivables0.030.110.143.063.077.557.160.270.320.32
Cash Equivalents 0.010.01002.510.1830.030.140.140.14
Others Assets0.450.661.124.774.737.689.158.728.618.53
Total Assets 4.325.317.8114.5427.4034.6165.6945.6045.2345.10

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'03Mar'04Mar'05Mar'06Mar'07Mar'08Mar'09Mar'10Mar'11Mar'12
Cash Flow From Operating Activity 0.020.580.55-3.611.79-1.650.78-9.56-0.47-0.11
PBT -0.130.100.611.682.151.75-0.97-20.64-0.60-0.18
Adjustment 0.07-0.02-0.280.032.421.471.190.640.120.12
Changes in Working Capital 0.080.520.37-5.04-2.78-4.870.5510.440.01-0.05
Tax Paid 0000000000
Cash Flow From Investing Activity 0-0.37-1.30-0.05-5.28-1.90-0.89-19.880.17-0.02
Capex 0-0.37-0.20-0.05-1.17-0.48-0.78-28.690.17-0.01
Net Investments 00-1.10000000-0.01
Others 0000-4.10-1.42-0.128.8100
Cash Flow From Financing Activity 0-0.220.743.665.991.2129.97-0.450.300.14
Net Proceeds from Shares 00000028.70000
Net Proceeds from Borrowing 0000000000
Interest Paid 0000-0.62-1.16-1.12-0.5200
Dividend Paid 0000000000
Others 0-0.220.743.666.612.372.390.070.300.14
Net Cash Flow 0.010002.50-2.3329.85-29.8900
PARTICULARSMar'03Mar'04Mar'05Mar'06Mar'07Mar'08Mar'09Mar'10Mar'11Mar'12
Ratios
ROE (%)-5.444.2825.6453.9640.9823.13-4.41-81.59-4.03-1.24
ROCE (%)-3.53.2821.7832.3222.4115.110.45-47.98-1.89-0.56
Asset Turnover Ratio0.040.531.030.890.60.650.20.0500
PAT to CFO Conversion(x)N/A5.80.9-2.150.83-0.94N/AN/AN/AN/A
Working Capital Days
Receivable Days611075989972634442,5600
Inventory Days102395055605010718300
Payable Days1,06331329331328622380092500

ABL Biotechnologies Ltd Stock News

ABL Biotechnologies Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of ABL Biotechnologies on 01-Jan-1970 05:30 is ₹0.00.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 01-Jan-1970 05:30 the market cap of ABL Biotechnologies stood at ₹0.66.
The latest P/E ratio of ABL Biotechnologies as of 01-Jan-1970 05:30 is 0.00.
The latest P/B ratio of ABL Biotechnologies as of 01-Jan-1970 05:30 is 0.05.
The 52-week high of ABL Biotechnologies is ₹0.81 and the 52-week low is ₹0.75.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of ABL Biotechnologies is ₹0.00 ( Cr.) .

About ABL Biotechnologies Ltd

ABL Biotechnologies incorporated in 1992, is a pioneer in harnessing the biodiversity of the Indian marine environment. ABL is engagaed in identification and commercial extraction of bio-chemicals, predominantly from microbes, that are used as nutritional, cosmetic, pharmaceutical, and industrial intermediates.

Company’s R&D unit is located at Vishakapatnam that has been recognised by the Department of Scientific and Industrial Research, Ministry of Science and Technology, Government of India.

Company’s microbial metabolites laboratory located at Chennai is focused on evaluating new sources of biochemicals from marine organisms.

Company has collaborated with institutions such as the National Facility for Marine Cyanobacteria, Bharathidasan University, Trichy, the National Institute of Oceanography, The Madras University and the Dr.A.L.M Post Graduate Institute of Medical Sciences, Madras to introduce joint development programmes of advanced research in India.

Company has taken various initiatives such as sale or licensing of technologies, development of biochemical intermediates, conducting research on aquatic biotechnology, product development for therapeutics industry and undertaking contract research. Under contract research company manufactures finished formulations in various formats including soft and hard gelatine capsules, tablets, liquid orals and topical ointments, for various disease states.

ABL has been conducting research on polysaccharides, essential fatty acids, natural pigments, tracers and tags with considerable success. Presently company is focus on developing pharmaceuticals products catering various areas like anti-bacterials and anti-virals, enzymes, bio-molecular materials, bio-monitors and diagnostics, bio-pesticides, bioremediation and aquaculture.

Product portfolio

Company manufactures Beta carotene, which is used as a source of Vitamin A for protection against strokes and cataracts, enhancing the immune system, and preventing photo sensitivity disorders.ABL manufactures Lycopene, an antioxidant carotenoid and pigment that gives characteristic red colour to tomatoes, watermelon, and pink grapefruit.Company developed Lutein, a carotenoid found in fruits and vegetables, including dark green and leafy vegetables, such as spinach and kale, as well as in foods comprising corn and egg yolks.ABL Biotechnologies involves in the production of carotenoid fortified products, including jams, squashes, ketchups and sauces, cooking oils, and chocolates.

Future Plan

ABL Biotechnologies R&D unit plans to strengthen its product portfolio by developing new molecules.

Read More Read Less
You have 0 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.